Krista works with pharmaceutical and biotech companies to find design-effective commercialization solutions.
With more than 20 years of experience in the pharmaceutical industry, Krista is an experienced sales representative and district manager, with strong client management, business development, and global account experience. Her work in clinical research, trials and development, as well as product launch experience, has been employed across numerous therapeutic areas including cardiology, oncology, neurology and urology.
Krista was recognized by the Healthcare Businesswoman’s Association as a Rising Star in 2012 and by both inVentiv Health and Alamo Pharma Services for her leadership, business results, and customer service. She holds a bachelor’s degree in science, communications and business ethics from the University of Delaware.
Articles by Krista Pinto
Established brands do not require significant proactive investment or attention from commercial teams and generate revenue for biopharma companies to reinvest and improve healthcare value for patients, providers and payers. Established brands have seen a decrease in utilization and patient access due to the pandemic, making them vulnerable to negative financial impacts that are difficult […]
EVERSANA™ REIGNITE Commercialization serves as a catalyst for biopharma companies to address the management of their established brand portfolios. In a recent study, EVERSANA reviewed a comprehensive number of established brands and implemented the EVERSANA REIGNITE Commercialization model to slow financial loss and make a positive impact on revenue. With a combined investment, these established […]
Krista Pinto, President, Deployment Solutions, participated in a panel alongside industry leaders at Reuters Events: Pharma USA 2022. The discussion analyzed how pharmaceutical salesforces must progress in tandem with rapidly evolving healthcare providers (HCPs) and illustrated EVERSANA’s unique ability to build efficient, future-focused field models that overcome market challenges. The onset of COVID-19 provided an […]
By applying transformative commercialization models, nurturing digital transformation and trailblazing in global expansion, we can get therapies to patients around the world who are still waiting for treatment options. For the past two years, the pharmaceutical industry has proven that it can adapt to change. In 2020, pharma pivoted to manage the coronavirus pandemic, and […]
The Power to Know When: Balancing High-Tech and High-Touch Solutions to Eliminate Access, Affordability and Adherence Barriers
Forty percent of consumers prefer speaking to a real person on the phone, and for more complex issues, 80% want to speak to a live service agent. In the increasingly virtual world we live in, one thing remains clear: we still crave human interactions. As a result, pharma manufacturers need to understand how patients and […]
Forty percent of worldwide drug launches between 2009 and 2017 failed to meet their two-year sales forecasts. Manufacturers can’t afford to overlook the full potential of a data-driven omnichannel strategy. Omnichannel success requires a comprehensive suite of pivotal datasets and a data-driven technology model that provides real-time visibility into the impact of sales calls and […]
Go beyond marketing to provide actionable insights that better inform commercial strategies and elevate brand success. EVERSANA’s best-in-class omnichannel activation model aggregates and synthesizes pivotal datasets from marketing campaigns, patient services programs and field activities to analyze and predict trends and behaviors that better inform promotional and support strategies. Serving as a seamless router of actionable data and […]
Omnichannel strategies are transforming the way consumers interact with brands across industries – from the all-in-one Magic Band experience at Disney to buying your favorite latte with the Starbucks app. The pharmaceutical industry is no exception, constantly evolving and implementing omnichannel strategies to reach patients and providers with truly personalized, timely engagement. But unlike all […]
From ordering your daily Starbucks latte on your iPhone to skipping the line at Splash Mountain with your Disney Magic Band, omnichannel strategies transform how consumers interact with their favorite brands. The most successful brands create an immersive experience that meets the needs of their consumers with a personalized touch. Instead of falling for the […]
The impact of COVID is reverberating across all aspects of society and business. In the healthcare industry, hundreds of thousands of patients are not getting proper access to and utilization of therapies that can improve their clinical outcomes. The clinical consequences of this will lead to compromised patient outcomes and further healthcare cost increases. This […]
The world will be moving forward with immeasurable effects from the COVID-19 pandemic, as will the pharmaceutical industry. Fully understanding the impact that the pandemic will have on pharma will take years; however, there are future indications emerging for mature brands. Mature brands, or non-promoted in-line brands, are the bread-and-butter products for pharma companies in […]
In the midst of a global pandemic, the role of commercial field teams evolved right before our eyes. Digital sales aids and tele-detailing are now mandatory sales tactics in a virtual Provider-Rep engagement. Now that field teams are starting to settle into “the new normal,” manufacturers are turning their attention to the next phase: make […]
Fact: Primary stakeholders – providers, patients and payers – have greater expectations than ever before. To ensure success at every stage of the product life cycle, it’s imperative to deploy a sophisticated, clinically oriented and data-driven field force who can demonstrate value to all three: Creating value for providers means presenting real-world evidence of positive […]
The pharmaceutical industry is complex. A litany of companies and brands are competing for top-of-mind usage with clinicians, a cohesive partnership with payers, and active engagement with patients. It’s hard enough to bring a drug to market, but how do brands keep their products positioned appropriately with limited resources, data and time? EVERSANA’s Executive Vice […]